Miscellaneous cannabinoids Clause Samples

Miscellaneous cannabinoids. The psychotropic activities of cannabinoids are well known (▇▇▇▇▇ and ▇▇▇▇▇▇▇, 1973; ▇▇▇▇▇▇▇▇▇▇▇ and ▇’▇▇▇▇▇, 2006); however, in clinical studies, in vitro and in vivo, some other pharmacological effects of cannabinoids are observed such as antinociceptive, antiepileptic, cardiovascular, immunosuppressive (Ameri, 1999), antiemetic, appetite stimulation (Mechoulam and ▇▇▇ ▇▇▇▇▇▇, 1999), antineoplastic (▇▇▇▇▇▇▇▇ et al., 1976; ▇▇▇▇▇ et al., 2004), antimicrobial (ElSohly et al., 1982), anti-inflammatory (▇▇▇▇▇▇▇▇▇ et al., 1988), neuroprotective antioxidants (▇▇▇▇▇▇▇ et al., 1988) and positive effects in psychiatric syndromes, such as depression, anxiety and sleep disorders (Grotenhermen, 2002; Musty, 2004). These effects could be due to agonistic nature of these compounds with respect to the cannabinoid CB1- and CB2 receptors (▇▇▇▇▇▇▇ et al., 1990; ▇▇▇▇▇ et al., 1993) which compete with endocannabinoids (▇▇▇▇▇▇▇▇▇ et al., 1998), a family of cannabinoid receptor ligands participating in modulation of neurohumoral activity (▇▇ ▇▇▇▇▇ et al., 2007; ▇▇▇▇▇▇▇▇▇ et al., 1999; ▇▇▇▇▇▇▇ et al., 2005). Some therapeutic applications from cannabis, cannabinoids, cannabinoid analogs and CB receptor agonist/antagonist are shown in table 1. Table 1. Some pharmacological applications of medicinal cannabis, THC, analogs and others. Product Components/ active ingredient Prescription/ clinical effects Administering Country Reference/ Company Cannabis flos variety Bedrocan® Cannabis flos Dry flowers, 18% Δ9-THC and 0.2% CBD Spasticity with pain in MS or spinal cord injury; nausea and vomiting by radiotherapy, chemotherapy and HIV-medication; chronic neuralgic pain and Gilles de la Tourette Syndrome; palliative treatment of cancer and HIV/AIDS Spasticity with pain in MS or spinal cord injury; Smoking NL Office of Medicinal Cannabis (OMC) Smoking NL Office of Medicinal variety Bedrobinol® Dry flowers, 13% Δ9-THC and